About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
https://soho2018.org/
Session I: Chronic Myeloid Leukemia
Session II: Myelodysplastic Syndromes
Session III: Myeloproliferative Neoplasms
Session IV: Acute Lymphoblastic Leukemia
Session V: Acute Myeloid Leukemia
Plenary Sessions
Breakfast with the Expert
Session VI: Multiple Myeloma
Program of Events
Session VIII: Non-Hodgkin Lymphoma
Session IX: Chronic Lymphocytic Leukemia
Session X: Research Topics
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Novel Agents, Antibodies, Targeted Therapies and Related Studies in Myeloma
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Thomas Martin
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Thomas Martin
255 views
October 24, 2018
1 Comment
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Session VI: Multiple Myeloma
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Myeloma State of the Art Update: Bone Disease, MRD Assessment, How t…
Feat.
S. Lonial
15:37
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
How Does Genetics and MRD Impact Myeloma Treatment Or Doesn’t It?
Feat.
A. Nooka
17:59
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Novel Agents, Antibodies, Targeted Therapies and Related Studies in …
Feat.
T. Martin
17:43
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Management and Diagnosis of Amyloid: What Is New?
Feat.
S. Lentzsch
17:17
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Emerging Data on Management and Imaging of Myeloma Bone Disease
Feat.
M. Dimopoulos
14:43
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?
Feat.
R. Orlowski
15:45
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
The Role of ASCT In The Era of Modern MM Therapy
Feat.
P. Voorhees
07:13
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Oral Abstract MM 107: Overall Survival of Patients Post-Transplant: …
Feat.
R. Abonour
16:22
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study
Feat.
S. Jagannath
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, M…
Feat.
S. Jagannath
